Business
Harvest One Announces Completion of Phase I of the Shoppers Drug Mart & TruTrace Technologies Pilot Program for Validation of Medical Cannabis
Harvest One Announces Completion of Phase I of the Shoppers Drug Mart & TruTrace Techn...
About this update from Delivra Health Brands Inc
[{"type":"text","content":"\n\n\n\nHarvest One Announces Completion of Phase I of the Shoppers Drug Mart & TruTrace Technologies Pilot Program for Validation of Medical Cannabis\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nHarvest One Announces Completion of Phase I of the Shoppers Drug Mart & TruTrace Technologies Pilot Program for Validation of Medical Cannabis\nCanada NewsWire\nVANCOUVER, Aug. 14, 2019\n\n\n\nVANCOUVER, Aug. 14, 2019 /CNW/ - Harvest One Cannabis Inc. (\"Harvest One\" or the \"Company\")(TSX-V: HVT; OTCQX: HRVOF) is pleased to announce that the Company's wholly-owned subsidiary, United Greeneries Ltd. (\"United Greeneries\"), has completed Phase I of a pilot program (the \"Pilot Program\") in conjunction with Shoppers Drug Mart (\"Shoppers\") and TruTrace Technologies Inc. (\"TruTrace\")(CSE: TTT; OTCQB: TTTSF) designed to increase the transparency and validation of products within the medical cannabis industry. \n\n \n \n\n \nThe Pilot Program uses the StrainSecure™ technology as a master registry for standardized testing, product verification, and quality assurance. Under StrainSecure™, plant testing data and genomic verification for each plant batch is utilized for intellectual property protection and strain validation.\nAs recently announced by Shoppers, Phase 1 of the Pilot Program has been completed and United Greeneries successfully met all of the requirements of Phase 1 due in part to their early adoption of TruTrace's StrainSecure™ platform and implementation of the Master Genome Strain and Clone Registration Program. Phase 2 is expected to run until late November, followed by full production and implementation. \n\"Now that we have completed Phase 1 of the Pilot Project, medically-registered patients can have an increased level of confidence in the consumption of our Satipharm branded cannabis through Shoppers\" said Grant Froese, CEO of Harvest One. \"We are delighted to be a part of this groundbreaking effort that is leading the way towards transparency and traceability within the medical cannabis industry.\"\n\"Harvest One h...